SpringWorks Therapeutics (SWTX)
(Delayed Data from NSDQ)
$34.38 USD
-0.97 (-2.74%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $34.38 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum D VGM
Price, Consensus and EPS Surprise
SWTX 34.38 -0.97(-2.74%)
Will SWTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SWTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SWTX
Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report?
Why Is SpringWorks Therapeutics (SWTX) Up 11.7% Since Last Earnings Report?
SWTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Predict a 61.05% Upside in SpringWorks Therapeutics (SWTX): Here's What You Should Know
SWTX's NDA for Rare Tumor Drug Gets Priority Review From FDA
Here's Why You Should Invest in SpringWorks (SWTX) Stock Now
Other News for SWTX
Deep Track Capital, LP Increases Stake in Dynavax Technologies Corp
Springworks Therapeutics: Promising Outlook for Ogsiveo Drives Overweight Rating and Elevated Price Target
SpringWorks Therapeutics price target raised by $4 at JPMorgan, here's why
SpringWorks Therapeutics Inc (SWTX) CEO Saqib Islam Sells 49,000 Shares
Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q2 2024 Update